Literature DB >> 24966274

Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease.

Beatriz Talayero1, Liyun Wang1, Jeremy Furtado1, Vincent J Carey2, George A Bray3, Frank M Sacks1.   

Abstract

Human HDLs have highly heterogeneous composition. Plasma concentrations of HDL with apoC-III and of apoE in HDL predict higher incidence of coronary heart disease (CHD). The concentrations of HDL-apoA-I containing apoE, apoC-III, or both and their distribution across HDL sizes are unknown. We studied 20 normal weight and 20 obese subjects matched by age, gender, and race. Plasma HDL was separated by sequential immunoaffinity chromatography (anti-apoA-I, anti-apoC-III, anti-apoE), followed by nondenaturing-gel electrophoresis. Mean HDL-cholesterol concentrations in normal weight and obese subjects were 65 and 50 mg/dl (P = 0.009), and total apoA-I concentrations were 119 and 118 mg/dl, respectively. HDL without apoE or apoC-III was the most prevalent HDL type representing 89% of apoA-I concentration in normal weight and 77% in obese (P = 0.01) individuals; HDL with apoE-only was 5% versus 8% (P = 0.1); HDL with apoC-III-only was 4% versus 10% (P = 0.009); and HDL with apoE and apoC-III was 1.5% versus 4.6% (P = 0.004). Concentrations of apoE and apoC-III in HDL were 1.5-2× higher in obese subjects (P ≤ 0.004). HDL with apoE or apoC-III occurred in all sizes among groups. Obese subjects had higher prevalence of HDL containing apoE or apoC-III, subfractions associated with CHD, whereas normal weight subjects had higher prevalence of HDL without apoE or apoC-III, subfractions with protective association against CHD.
Copyright © 2014 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  apolipoprotein A-I; coronary heart disease; high density lipoprotein size

Mesh:

Substances:

Year:  2014        PMID: 24966274      PMCID: PMC4174008          DOI: 10.1194/jlr.M042333

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  52 in total

1.  Isolation of subpopulations of high density lipoproteins: three particle species containing apoE and two species devoid of apoE that have affinity for heparin.

Authors:  L K Hennessy; S T Kunitake; M Jarvis; R L Hamilton; G Endeman; A Protter; J P Kane
Journal:  J Lipid Res       Date:  1997-09       Impact factor: 5.922

2.  Altered properties of high density lipoprotein subfractions in obese subjects.

Authors:  T Sasahara; T Yamashita; D Sviridov; N Fidge; P Nestel
Journal:  J Lipid Res       Date:  1997-03       Impact factor: 5.922

3.  Pre beta 1-high-density lipoprotein increases in coronary artery disease.

Authors:  T Miida; Y Nakamura; K Inano; T Matsuto; T Yamaguchi; T Tsuda; M Okada
Journal:  Clin Chem       Date:  1996-12       Impact factor: 8.327

4.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

5.  Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia.

Authors:  H Campos; D Perlov; C Khoo; F M Sacks
Journal:  J Lipid Res       Date:  2001-08       Impact factor: 5.922

6.  Regulation of reconstituted high density lipoprotein structure and remodeling by apolipoprotein E.

Authors:  Kerry-Anne Rye; Richard Bright; Maria Psaltis; Philip J Barter
Journal:  J Lipid Res       Date:  2006-02-01       Impact factor: 5.922

7.  Effect of torcetrapib on the progression of coronary atherosclerosis.

Authors:  Steven E Nissen; Jean-Claude Tardif; Stephen J Nicholls; James H Revkin; Charles L Shear; William T Duggan; Witold Ruzyllo; William B Bachinsky; Gabriel P Lasala; Gregory P Lasala; E Murat Tuzcu
Journal:  N Engl J Med       Date:  2007-03-26       Impact factor: 91.245

8.  Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  A R Sharrett; C M Ballantyne; S A Coady; G Heiss; P D Sorlie; D Catellier; W Patsch
Journal:  Circulation       Date:  2001-09-04       Impact factor: 29.690

9.  Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography.

Authors:  Scott M Gordon; Jingyuan Deng; L Jason Lu; W Sean Davidson
Journal:  J Proteome Res       Date:  2010-10-01       Impact factor: 4.466

10.  Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease.

Authors:  Majken K Jensen; Eric B Rimm; Jeremy D Furtado; Frank M Sacks
Journal:  J Am Heart Assoc       Date:  2012-04-24       Impact factor: 5.501

View more
  20 in total

1.  Using primary murine intestinal enteroids to study dietary TAG absorption, lipoprotein synthesis, and the role of apoC-III in the intestine.

Authors:  Javeed Jattan; Cayla Rodia; Diana Li; Adama Diakhate; Hongli Dong; Amy Bataille; Noah F Shroyer; Alison B Kohan
Journal:  J Lipid Res       Date:  2017-02-03       Impact factor: 5.922

2.  Distinct Proteomic Signatures in 16 HDL (High-Density Lipoprotein) Subspecies.

Authors:  Jeremy D Furtado; Rain Yamamoto; John T Melchior; Allison B Andraski; Maria Gamez-Guerrero; Patrick Mulcahy; Zeling He; Tianxi Cai; W Sean Davidson; Frank M Sacks
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-12       Impact factor: 8.311

3.  Dietary unsaturated fat increases HDL metabolic pathways involving apoE favorable to reverse cholesterol transport.

Authors:  Allyson M Morton; Jeremy D Furtado; Carlos O Mendivil; Frank M Sacks
Journal:  JCI Insight       Date:  2019-04-04

Review 4.  ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.

Authors:  Natalia A Rocha; Cara East; Jun Zhang; Peter A McCullough
Journal:  Curr Atheroscler Rep       Date:  2017-11-09       Impact factor: 5.113

5.  Associations of anthropometry and lifestyle factors with HDL subspecies according to apolipoprotein C-III.

Authors:  Manja Koch; Jeremy D Furtado; Gordon Z Jiang; Brianna E Gray; Tianxi Cai; Frank Sacks; Anne Tjønneland; Kim Overvad; Majken K Jensen
Journal:  J Lipid Res       Date:  2017-04-01       Impact factor: 5.922

6.  Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk.

Authors:  Allyson M Morton; Manja Koch; Carlos O Mendivil; Jeremy D Furtado; Anne Tjønneland; Kim Overvad; Liyun Wang; Majken K Jensen; Frank M Sacks
Journal:  JCI Insight       Date:  2018-02-22

7.  Protein-Defined Subspecies of HDLs (High-Density Lipoproteins) and Differential Risk of Coronary Heart Disease in 4 Prospective Studies.

Authors:  Frank M Sacks; Liang Liang; Jeremy D Furtado; Tianxi Cai; W Sean Davidson; Zeling He; Robyn L McClelland; Eric B Rimm; Majken K Jensen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-09-10       Impact factor: 8.311

Review 8.  Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease.

Authors:  Alison B Kohan
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-04       Impact factor: 3.243

Review 9.  From High-Density Lipoprotein Cholesterol to Measurements of Function: Prospects for the Development of Tests for High-Density Lipoprotein Functionality in Cardiovascular Disease.

Authors:  Frank M Sacks; Majken K Jensen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-01-25       Impact factor: 8.311

10.  The association between the DNAH11 rs10248618 SNP and serum lipid traits, the risk of coronary artery disease, and ischemic stroke.

Authors:  Yong-Gang Zhou; Rui-Xing Yin; Jie Wu; Qing-Hui Zhang; Wu-Xian Chen; Xiao-Li Cao
Journal:  Int J Clin Exp Pathol       Date:  2018-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.